Pharming Group (NASDAQ:PHAR) Given Buy Rating at HC Wainwright

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $37.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 297.00% from the company’s previous close.

A number of other research firms have also recently weighed in on PHAR. Jefferies Financial Group started coverage on Pharming Group in a report on Monday. They set a “buy” rating and a $14.00 price target on the stock. Oppenheimer cut their target price on Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th.

Pharming Group Trading Up 0.5 %

Shares of NASDAQ:PHAR opened at $9.32 on Wednesday. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The company’s 50-day moving average price is $8.25 and its 200 day moving average price is $8.15. The company has a market cap of $632.22 million, a PE ratio of -35.85 and a beta of 0.05. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.